Rapid Micro Biosystems, Inc.
RPIDHealthcareNASDAQMedical Devices · Last scanned Sep 8, 2026
Scan Results
Daily timeframeRapid Micro Biosystems, Inc., a life sciences technology company, provides products for the detection of microbial contamination in the manufacture of pharmaceutical, biologics, medical devices, and. The company carries a $65.7M market cap, placing it firmly in the micro-cap category. The company offers Growth Direct platform, which includes growth direct system, proprietary consumables, lab information management system connection software, and customer support and validation services.
Market Cap
$65.7M
Beta
1.44
P/E (TTM)
—
P/E (Fwd)
-1.80
EPS (TTM)
$-1.12
EPS (Fwd)
$-0.73
ROE
-141.7%
ROA
-46.4%
Cash
$20.5M
Total Debt
$23.5M
Free CF
-$21.4M
52W Change
-50.8%
Annual Financials
Cash vs Debt
Where RPID stands vs its 150-day and 200-day moving averages
As of the September 3, 2026 close, RPID finished 43.50% below its 150-day moving average ($2.46) and 50.00% below its 200-day moving average ($2.78). This snapshot is end-of-day data shown with a five-trading-day delay on the free plan; Premium members see readings from the latest close.
Is RPID overbought or oversold?
At the September 3, 2026 close, RPID's RSI(14) was 26.1, in oversold territory (below 30). The MACD histogram was negative, so short-term momentum leaned bearish at that close. These readings are historical, refresh daily after market close, and are not investment advice.
The company holds $20.5M in cash, though total debt stands at $23.5M. This level of leverage is common in the industry but worth monitoring as interest rate conditions evolve. Free cash flow is running at -$21.4M, which bears watching. Negative free cash flow can be acceptable during heavy investment periods but needs to improve over time. Return on equity stands at -141.7%, which is negative for the sector. ROE measures how effectively a company uses shareholder capital to generate profits. Revenue has grown from $17.1M (2022) to $33.6M (2025), reflecting a 96% increase over the period.
Negative free cash flow means the company is currently spending more than it generates, which may require future fundraising or debt if the trend continues. Understanding these risk dimensions helps frame what to watch going forward as conditions evolve for Rapid Micro Biosystems, Inc. and its sector.